20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization

Journal of Pathology

Volumn 190, Issue 5, 2000, Pages 564-571

  Diebold, Joachim ^a   Mösinger, Kerstin ^a   Peiro, Gloria ^a   Pannekamp, Uwe ^a   Kaltz, Christine ^a   Baretton, Gustavo B ^a   Meier, Werner ^b   Löhrs, Udo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

20q13; Cyclin D1; FISH; Immunohistochemistry; Ovarian carcinoma

Indexed keywords

CYCLIN D1;

ADULT; AGED; ARTICLE; CANCER STAGING; CHROMOSOME 20Q; CONTROLLED STUDY; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TISSUE FIXATION; TISSUE SECTION;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 20; CYCLIN D1; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PLOIDIES; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0342369458     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200004)190:5<564::AID-PATH569>3.0.CO;2-L     Document Type: Article

References (50)

1. Bjorge T, Engeland A, Sundfor K, Trope CG. Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Acta Obstet Gynecol Scand 1998; 77: 777-781.
2. Kawai M, Kikkawa F, Haltori S, Ohta M, Arii Y, Tomoda Y. Long-term follow-up of patients with epithelial carcinoma of the ovary. Int J Gynaecol Obstet 1994; 44: 259-266.
3. Scully RE, Young RH, Clement PB. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. Armed Forces Institute of Pathology: Washington, DC, 1998.
4. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. J Am Med Assoc 1995; 273: 491-497.
5. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998; 25: 326-334.
6. Braly PS, Klevecz RR. Flow cylometric evaluation of ovarian cancer. Cancer 1993; 71: 1621-1628.
7. Rice LW, Mark SD, Berkowitz RS, Goff BA, Lage JM. Clinicopathologic variables, operative characteristics, and DNA ploidy in predicting outcome in ovarian epithelial carcinoma. Obstet Gynecol 1995; 86: 379-385.
8. Reles AE, Gee C, Schellschmidt I, et al. Prognostic significance of DNA content and S-phase fraction in epithelial ovarian carcinomas analyzed by image cytometry. Gynecol Oncol 1998; 71: 3-13.
9. Silvestrini R, Daidone MG, Veneroni S, et al. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 1998; 82: 159-167.
10. Thompson FH, Emerson J, Alberts D, et al. Clonal chromosome abnormalities in 54 cases of ovarian carcinoma. Cancer Genet Cytogenet 1994; 73: 33-45.
11. Pejovic T. Genetic changes in ovarian cancer. Ann Med 1995; 27: 73-78.
12. Iwabuchi H, Sakamoto M, Sakunaga H, et al. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 1995; 55: 6172-6180.
13. Sonoda G, Palazzo J, du Manoir S, et al. Comparative genomic hybridisation detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer 1997; 20: 320-328.
14. Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol Pathol 1998; 51: 1-7.
15. Barnes DM. Cyclin D1 in mammary carcinoma. J Pathol 1997; 181: 267-269.
16. Tanner MM, Karhu RA, Nupponen NN, et al. Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. Am J Pathol 1998; 153: 191-199.
17. Tanner MM, Tirkkonen M, Kallioniemi A, et al. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res 1995; 1: 1455-1461.
18. Tanner MM, Tirkkonen M, Kallioniemi A, et al. Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res 1996; 56: 3441-3445.
19. Courjal F, Cuny M, Rodriguez C, et al. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. Br J Cancer 1996; 74: 1984-1989.
20. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998; 82: 893-901.
21. Hyytinen E, Visakorpi T, Kallioniemi A, Kallioniemi OP, Isola JJ. Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridisation. Cytometry 1994; 16: 93-99.
22. Baretton G, Diebold J, DePascale T, Bussar-Maatz R, Weissbach L, Löhrs U. Deoxyribonucleic acid ploidy in seminomas with and without syncytiotrophoblastic cells. J Urol 1994; 151: 67-71.
23. Persons DL, Hartmann LC, Herath JF, et al. Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. Am J Pathol 1993; 142: 733-741.
24. Diebold J, Deisenhofer I, Baretton GB, et al. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas. Lab Invest 1996; 75: 473-485.
25. Wolf NG, Abdul-Karim FW, Schorck NJ, Schwartz S. Origins of heterogeneous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential, and fully malignant components. Am J Pathol 1996; 149: 511-520.
26. Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993; 259: 1908-1912.
27. Quelle DE, Ashmun RA, Shurtleff SA, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993; 7: 1559-1571.
28. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994; 14: 1669-1679.
29. Rosenberg CL, Motokura T, Kronenberg HM, Arnold A. Coding sequence of the overexpressed transcript of the putative oncogene PRAD1/cyclin D1 in two primary human tumors. Oncogene 1993; 8: 519-521.
30. Rimokh R, Berger F, Bastard C, et al. Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood 1994; 83: 3689-3696.
31. Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8: 2127-2133.
32. Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812-1817.
33. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994; 57: 353-361.
34. Zhang SY, Caamano J, Cooper F, Guo X, Klein-Szanto AJ. Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol 1994; 102: 695-698.
35. Barbieri F, Cagnoli M, Ragni N, Pedulla F, Foglia G, Alama A. Expression of cyclin D1 correlates with malignancy in human ovarian tumours. Br J Cancer 1997; 75: 1263-1268.
36. Hung WC, Chai CY, Huang JS, Chuang LY. Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors. Hum Pathol 1996; 27: 1324-1328.
37. Worsley SD, Ponder BA, Davies BR. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 1997; 64: 189-195.
38. Masciullo V, Scambia G, Marone M, et al. Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. Int J Cancer 1997; 74: 390-395.
39. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996; 69: 247-253.
40. Hosokawa Y, Arnold A. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer 1998; 22: 66-71.
41. Collins C, Rommens JM, Kowbel D, et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A 1998; 95: 8703-8708.
42. Brinkmann U, Gallo M, Polymeropoulos MH, Pastan I. The human CAS (cellular apoptosis susceptibility) gene mapping on chromosome 20q13 is amplified in BT474 breast cancer cells and part of aberrant chromosomes in breast and colon cancer cell lines. Genome Res 1996; 6: 187-194.
43. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998; 17: 3052-3065.
44. Sen S, Zhou H, White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997; 14: 2195-2200.
45. Savelieva E, Belair CD, Newton MA, et al. 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells. Oncogene 1997; 14: 551-560.
46. Guan XY, Xu J, Anzick SL, Zhang H, Trent JM, Meltzer PS. Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within amplified region at 20q11 q13.2 in breast cancer. Cancer Res 1996; 56: 3446-3450.
47. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997; 277: 965-968.
48. Sauter G, Feichter G, Torhorst J, et al. Fluorescence in situ hybridisation for detecting erbB-2 amplification in breast tumour line needle aspiration biopsies. Acta Cytol 1996; 40: 164-173.
49. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridisation. Oncogene 1996; 13: 63-72.
50. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridisation: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894-2904.